Top-Rated StocksTop-RatedNASDAQ:EXAS Exact Sciences (EXAS) Stock Price, News & Analysis $70.27 -0.31 (-0.44%) (As of 10/23/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Exact Sciences Stock (NASDAQ:EXAS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Exact Sciences alerts:Sign Up Key Stats Today's Range$69.18▼$71.4350-Day Range$56.36▼$71.9352-Week Range$40.62▼$79.62Volume1.08 million shsAverage Volume2.56 million shsMarket Capitalization$12.97 billionP/E RatioN/ADividend YieldN/APrice Target$78.38Consensus RatingModerate Buy Company OverviewExact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.Read More… Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Exact Sciences Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks89th Percentile Overall ScoreEXAS MarketRank™: Exact Sciences scored higher than 89% of companies evaluated by MarketBeat, and ranked 119th out of 1,001 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingExact Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 14 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageExact Sciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Exact Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Exact Sciences are expected to grow in the coming year, from ($0.87) to ($0.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exact Sciences is -73.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exact Sciences is -73.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExact Sciences has a P/B Ratio of 4.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Exact Sciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.60% of the outstanding shares of Exact Sciences have been sold short.Short Interest Ratio / Days to CoverExact Sciences has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Exact Sciences has recently decreased by 14.56%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldExact Sciences does not currently pay a dividend.Dividend GrowthExact Sciences does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.83 Percentage of Shares Shorted7.60% of the outstanding shares of Exact Sciences have been sold short.Short Interest Ratio / Days to CoverExact Sciences has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Exact Sciences has recently decreased by 14.56%, indicating that investor sentiment is improving significantly. News and Social Media2.8 / 5News Sentiment1.10 News SentimentExact Sciences has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Exact Sciences this week, compared to 8 articles on an average week.Search Interest9 people have searched for EXAS on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Exact Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Exact Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $130,060.00 in company stock.Percentage Held by InsidersOnly 1.36% of the stock of Exact Sciences is held by insiders.Percentage Held by Institutions88.82% of the stock of Exact Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Exact Sciences' insider trading history. Receive EXAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address EXAS Stock News HeadlinesInsider Selling: Exact Sciences Co. (NASDAQ:EXAS) EVP Sells 929 Shares of StockOctober 10, 2024 | insidertrades.comCan This Beaten-Down Cathie Wood Stock Bounce Back?October 17, 2024 | fool.comWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonOctober 24, 2024 | Porter & Company (Ad)Exact Sciences Corporation (EXAS) Bounced Back in Q3October 16, 2024 | msn.com1 'Strong Buy' Healthcare Stock to Scoop Up After Its Latest FDA WinOctober 10, 2024 | msn.comExact Sciences Corp (EXAS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...October 9, 2024 | finance.yahoo.comExact Sciences Schedules Third Quarter 2024 Earnings CallOctober 8, 2024 | finance.yahoo.comBuy Rating on Exact Sciences: Anticipating Growth from Cologuard Plus and Strategic InitiativesOctober 7, 2024 | markets.businessinsider.comSee More Headlines EXAS Stock Analysis - Frequently Asked Questions How have EXAS shares performed this year? Exact Sciences' stock was trading at $73.98 on January 1st, 2024. Since then, EXAS shares have decreased by 5.0% and is now trading at $70.27. View the best growth stocks for 2024 here. How were Exact Sciences' earnings last quarter? Exact Sciences Co. (NASDAQ:EXAS) released its quarterly earnings data on Wednesday, July, 31st. The medical research company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.28. The firm's quarterly revenue was up 12.4% on a year-over-year basis. Does Exact Sciences have any subsidiaries? Exact Sciences subsidiaries include these companies: Ashion Analytics, Thrive Earlier Detection Corporation, Base Genomics Limited, Paradigm Diagnostics Inc., Viomics Inc., Biomatrica Inc., Armune BioScience, and more. Who are Exact Sciences' major shareholders? Exact Sciences' top institutional shareholders include International Assets Investment Management LLC (0.09%), Bank Pictet & Cie Europe AG (0.07%), Artemis Investment Management LLP (0.06%) and Stanley Laman Group Ltd. (0.05%). Insiders that own company stock include Kevin T Conroy, Sarah Condella, Katherine S Zanotti, James Edward Doyle, Everett Cunningham, D Scott Coward, Daniel J Levangie, Jacob A Orville, Brian Baranick, Jeffrey Thomas Elliott and James Herriott. View institutional ownership trends. How do I buy shares of Exact Sciences? Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Exact Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Exact Sciences investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Adobe (ADBE) and Arista Networks (ANET). Company Calendar Last Earnings7/31/2024Today10/23/2024Next Earnings (Confirmed)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostics & Research Sub-IndustryBiotechnology Current SymbolNASDAQ:EXAS CUSIP30063P10 CIK1124140 Webwww.exactsciences.com Phone(608) 284-5700Fax608-284-5701Employees6,500Year Founded1995Price Target and Rating Average Stock Price Target$78.38 High Stock Price Target$95.00 Low Stock Price Target$67.00 Potential Upside/Downside+11.5%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($1.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-204,150,000.00 Net Margins-6.70% Pretax Margin-6.59% Return on Equity-4.97% Return on Assets-2.41% Debt Debt-to-Equity Ratio0.73 Current Ratio2.17 Quick Ratio1.98 Sales & Book Value Annual Sales$2.61 billion Price / Sales4.96 Cash Flow$0.02 per share Price / Cash Flow4,023.32 Book Value$17.39 per share Price / Book4.04Miscellaneous Outstanding Shares184,530,000Free Float182,257,000Market Cap$12.97 billion OptionableOptionable Beta1.27 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:EXAS) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exact Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.